Boston, Massachusetts 2021-06-10 12:54:22 –
DDespite all the excitement surrounding FDA approval on Monday In the controversial treatment of Alzheimer’s disease, the drug does not immediately flow into the arms of many patients.
Created by Cambridge-based Biogen, Aduhelm is still unclear about how to offer an hourly infusion each month and whether insurers will pay for the drug despite the $ 56,000 annual price tag. It raises no set of nasty problems. In addition, some consumers may face significant out-of-pocket costs and may rethink taking medications with known risks and uncertain benefits.
What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead Source link What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead